Itepekimab (SAR440340)
Sponsors
Sanofi
Conditions
BronchiectasisChronic Obstructive Pulmonary DiseaseChronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis Without Nasal Polyps
Phase 2
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
CompletedNCT06280391
Start: 2024-02-20End: 2026-02-02Updated: 2026-02-12
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
CompletedNCT06691113
Start: 2024-12-16End: 2026-08-12Updated: 2026-08-25
Phase 3
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Active, not recruitingNCT06208306
Start: 2024-01-11End: 2026-12-01Target: 700Updated: 2026-05-18
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Active, not recruitingNCT06834360
Start: 2025-02-06End: 2027-10-11Updated: 2026-06-02
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Active, not recruitingNCT06834347
Start: 2025-02-12End: 2027-09-16Updated: 2026-05-20
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
Active, not recruitingNCT07424144
Start: 2026-03-12End: 2027-02-17Updated: 2026-08-12
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
WithdrawnNCT07484230
Start: 2026-05-08End: 2028-10-10Updated: 2026-08-13